Questions
What exactly do I receive each week?
Every Friday morning you receive an email containing 15-20 tagged signals from the week's biopharma news. Each signal includes the event, the companies involved, relevant data points, and specific action items for your service category (CRO, CDMO, recruiting, legal, agency, or clinical tech). The brief also includes a "Who To Call This Week" list with 10 prioritized targets, the person to contact, and a suggested opening line.
How is this different from reading the BioMed Nexus newsletter?
The free daily newsletter is editorial analysis written for biotech professionals who want to stay informed. Signals is a sales tool built for BD teams who need to act on that information. The newsletter tells you what happened. Signals tells you who to call because of what happened, and what to say when they pick up.
What types of signals do you track?
M&A and acquisitions, venture funding and IPOs, clinical trial milestones (Phase completions, data readouts, pivotal trial starts), regulatory events (FDA approvals, breakthrough designations, PDUFA dates), leadership changes (C-suite appointments, board changes), and market trends (patent cliff activity, therapeutic area shifts, policy changes).
Can I try it before committing?
Yes. We offer a 2-week free trial — two full signals briefs with no commitment. If your team doesn't find it actionable, you pay nothing.
How do I justify this to my leadership?
Your BD team spends 10+ hours per week researching prospects and building outreach lists. Signals reduces that to 15 minutes on Friday morning. At a fully loaded BD salary of $150,000+, the time savings alone justify the subscription. One closed deal from a signal-driven outreach covers the cost for the next decade.
What does the co-branded lead magnet look like?
Once per quarter, we produce a polished industry report — for example, "The 2026 Biotech Outsourcing Landscape" — with your company's branding alongside BioMed Nexus. Your BD team distributes it to prospects as a value-add. It positions your company as a thought leader while generating conversations. We write it. You brand it. Your team uses it.
How is the data sourced?
Signals is built on the BioMed Nexus editorial engine — the same research that powers our daily brief reaching 65,000+ biotech professionals. Our editorial team monitors FDA filings, SEC disclosures, clinical trial registries, earnings calls, press releases, and industry databases daily. Signals restructures that intelligence into actionable format.
